Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Transcription-coupled nucleotide excision repair (TC-NER) is a specialized subpathway of nucleotide excision repair (NER) that specifically repairs DNA damage on actively transcribed strands. Unlike global genomic NER (GG-NER) which uses surveillance proteins like XPC to recognize damage, TC-NER utilizes elongating RNA polymerase II (Pol II) to scan the transcribed strand and identify transcription-stalling damage[1]. The TC-NER process begins when RNA polymerase II stalls at a DNA lesion. This triggers the recruitment of specific TC-NER factors, including CSB (or its counterparts Rad26 in yeast and Mfd in bacteria), which helps displace the transcription elongation factor Spt4-Spt5 in regions downstream of the transcription start site[1]. After damage recognition, both TC-NER and GG-NER pathways converge by recruiting transcription factor IIH (TFIIH), a ten-subunit complex containing the DNA helicases XPD and XPB[1][2]. TFIIH, along with XPA and replication protein A (RPA), unwinds the DNA strands around the damage site and verifies the presence of the lesion[1]. This creates a preincision DNA bubble that is recognized by repair endonucleases ERCC1-XPF and XPG, which make incisions on the 5' and 3' sides of the damage, respectively[1][2]. This dual incision results in the removal of a single-stranded DNA fragment of approximately 25-30 nucleotides containing the lesion[1][2]. Following excision, replication factor C (RFC) loads the Proliferating Cell Nuclear Antigen (PCNA) onto the DNA strand, allowing DNA polymerases (δ, ε and/or κ) to fill the gap using the undamaged strand as a template[2]. Finally, DNA ligase I or the ligase III-XRCC1 complex seals the nicks to complete the repair process[1][2]. Recent genomic approaches have revealed that TC-NER may have broader functions than previously thought, including the repair of non-bulky base damage when base excision repair (BER) is deficient[1]. Defects in TC-NER components can lead to severe human disorders, including xeroderma pigmentosum, which increases skin cancer risk by 1000-fold in homozygous patients[2]. Additionally, polymorphisms in TC-NER genes have been associated with cancer prognosis, with the XPD polymorphism 2251A>C significantly correlated with early relapse in colorectal cancer patients after chemotherapy[2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Transcription-coupled nucleotide excision repair (TC-NER) complex (TC-NER).